Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Merck is the latest big drugmaker to take aim at KRAS, signing a $50 million upfront, $2.5 billion biobucks deal Monday with Taiho and Astex for small molecule…
Merck has signed a research collaboration with Taiho Pharmaceutical and Astex Pharmaceuticals worth up to $2.5 billion in milestones for small-molecule…
Merck's $2.5 billion biobucks deal with Taiho and Astex announced Monday officially makes KRAS the hottest oncology BD target of 2020. Amgen leads with AMG…
Source summaries from our enrichment pipeline; follow links for originals.
All 8 sources with sentiment breakdown →
Merck entered an exclusive worldwide research collaboration and license agreement with Taiho Pharmaceutical and Astex Pharmaceuticals for small molecule inhibitors against several drug targets including the KRAS oncogene. Taiho and Astex received $50M upfront and are eligible for up to ~$2.5B in milestones plus tiered royalties. Taiho retained co-commercialization rights in Japan and an option to promote in parts of Southeast Asia.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Merck & Co. Inc. / Taiho Pharmaceutical / Astex Pharmaceuticals (this deal) | 2020 | $2.5B | — |
| Merck & Co. Inc. / Acceleron Pharma Inc. | 2021 | $11.5B | 90 |
| Merck & Co. Inc. / Peloton Therapeutics Inc. | 2019 | $2.2B | 88 |
| Merck & Co. Inc. / AstraZeneca PLC | 2017 | $8.5B | 87 |
| Merck & Co. Inc. / Moderna, Inc. | 2022 | $250M | 86 |
| Merck & Co. Inc. / Moderna, Inc. | 2016 | $250M | 84 |
| Merck & Co. Inc. / Eisai Co., Ltd. | 2018 | $5.8B | 83 |
← Browse all deals · How we score deals
More: 2020 deals · Merck & Co. Inc. deals · Oncology deals